Phase I trial for the Prevention of Cytokine Release Syndrome (CRS) with Cyclosporine in Patients with Moderate COVID-19
Brief description of study
Recruiting hospitalized patients within Penn Medicine
The purpose of this study is to determine if it is safe to take Cyclosporine for up to two
weeks in patients who have COVID-19 infection. The reason this is important for people
afflicted with the COVID-19 virus is that an over active immune system leading to cytokine
release syndrome is thought to cause death in some patients. The long-term goal of this
research is to learn if Cyclosporine can prevent or decrease the risk of cytokine release
syndrome.
Detailed description of study
The research study is being conducted to learn why some people get very sick from
COVID-19. This study will test whether some people make more immune responses in the
blood, and that this is an overreaction to the virus. This reaction can actually lead to harm
and cause more damage in the lungs, leading to more difficulty breathing. By volunteering
to be on this study, you would be treated with Cyclosporine, a drug that suppresses the
immune response. You would take the drug for up to 2 weeks, or until you are discharged
from the hospital, whichever comes first.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
COVID
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
13 Jul 2021.
Study ID: 842998
